Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Landgraf-Leurs, M. M.
Right arrow Articles by Landgraf, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Landgraf-Leurs, M. M.
Right arrow Articles by Landgraf, R.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 39, Issue 3 369-375, Copyright © 1990 by American Diabetes Association

ARTICLES

Pilot study on omega-3 fatty acids in type I diabetes mellitus

MM Landgraf-Leurs, C Drummer, H Froschl, R Steinhuber, C Von Schacky and R Landgraf
Department of Internal Medicine, Innenstadt, University of Munich, Federal Republic of Germany.

Patients with diabetes mellitus are prone to develop vascular complications. Because omega-3 polyunsaturated fatty acid (omega 3FA) intake has a potential protective effect on cardiovascular disease, we studied the influence of omega 3FA supplementation (5.4 g eicosapentaenoic acid and 2.3 g docosahexaenoic acid daily) for 4 wk in 13 well-controlled type I (insulin-dependent) diabetic subjects on a vascular risk profile. Each subject served as his/her own control in a pre- and post-omega 3FA-intake phase. In plasma and platelets, phospholipids eicosapentaenoic acid and docosahexaenoic acid increased at the expense of arachidonic acid and linoleic acid. There was no significant change in blood pressure and glycosylated proteins. Only small changes were noted in blood glucose levels and insulin dose. Side effects were not noted. Triglycerides decreased significantly in the first 14 days, and total cholesterol increased slightly, probably because of an elevation of high-density lipoprotein cholesterol, although low-density lipoprotein cholesterol remained unchanged. Platelet aggregation induced by low doses of ADP and collagen, which was higher in diabetic than nondiabetic subjects, decreased during omega 3FA intake to levels of healthy control subjects. Thromboxane production after ADP- and collagen-induced platelet aggregation decreased significantly. Thromboxane liberation during clotting of whole blood and urinary excretion of thromboxane were markedly lowered during omega 3FA supplementation. The results show that even short-term intake of omega 3FAs leads to beneficial changes of vascular risk factors without significant changes in glucose homeostasis.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Diabetes CareHome page
R. De Caterina, R. Madonna, A. Bertolotto, and E. B. Schmidt
n-3 Fatty Acids in the Treatment of Diabetic Patients: Biological rationale and clinical data
Diabetes Care, April 1, 2007; 30(4): 1012 - 1026.
[Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
E. Dewailly, C. Blanchet, S. Gingras, S. Lemieux, and B. J. Holub
Cardiovascular disease risk factors and n-3 fatty acid status in the adult population of James Bay Cree
Am. J. Clinical Nutrition, July 1, 2002; 76(1): 85 - 92.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
W. E. Connor
Diabetes, Fish Oil, and Vascular Disease
Ann Intern Med, December 15, 1995; 123(12): 950 - 952.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1990 by the American Diabetes Association.